Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A | P35498 | 4/20 | 1.00 |
| ▸ | SCN2A | Q99250 | 4/20 | 1.00 |
| ▸ | SCN3A | Q9NY46 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 12/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.81 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.81 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.81 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.81 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.81 |
| ▸ | HPGD | P15428 | 3/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.81 |
| ▸ | TSHR | P16473 | 2/20 | 0.81 |
| ▸ | MEN1 | O00255 | 2/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.81 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.81 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.81 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.60 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25906 | 1.00 | SCN1A (1.00) | SCN1ASCN2ASCN3ACYP2D6KDM4E | |
| SCHEMBL29756213 | 1.00 | SCN1A (1.00) | SCN1ASCN2ASCN3ACYP2D6KDM4E | |
| Hydrochloric Acid SCHEMBL590796 | 0.99 | SCN1A (0.98) | SCN1ASCN2ASCN3ACYP2D6KDM4E | |
| Hydrochloric Acid SCHEMBL1004227 | 0.99 | SCN1A (0.98) | SCN1ASCN2ASCN3ACYP2D6KDM4E | |
| Hydrochloric Acid SCHEMBL9418868 | 0.98 | SCN1A (0.97) | SCN1ASCN2ASCN3ACYP2D6KDM4E | |
| Ethylhydrocupreine SCHEMBL29361889 | 0.93 | CYP2D6 (0.89) | SCN1ASCN2ASCN3ACYP2D6KDM4E | |
| Ethylhydrocupreine SCHEMBL467210 | 0.93 | CYP2D6 (0.89) | SCN1ASCN2ASCN3ACYP2D6KDM4E | |
| Ethylhydrocupreine SCHEMBL31285607 | 0.92 | CYP2D6 (0.88) | SCN1ASCN2ASCN3ACYP2D6KDM4E | |
| Ethylhydrocupreine SCHEMBL3866393 | 0.92 | CYP2D6 (0.88) | SCN1ASCN2ASCN3ACYP2D6KDM4E | |
| Hydroquinidine SCHEMBL25429352 | 0.89 | CYP2D6 (1.00) | SCN1ASCN2ASCN3ACYP2D6KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1910 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115156-A1 | INJECTABLE COMPOSITION INCLUDING HYDROGEL CONTAINING ANESTHETIC AGENT | UNIV KOREA RES & BUS FOUND (KR) | 2026-04-30 | — | — | US | claimed |
| WO-2025235864-A1 | COATED NEEDLE ADMINISTRATION SYSTEMS | EVOLUS, INC. (US) | 2025-11-13 | — | — | WO | claimed |
| US-12329856-B2 | Crosslinked hyaluronic acid composition with local anesthetics | BIOPOLIMERI S.R.L. (IT) | 2025-06-17 | — | — | US | claimed |
| US-20250186364-A1 | COMBINATION OF ANTISPASMODIC AND ANESTHETIC AGENTS FOR TOPICAL PRODUCTS AND THEIR METHOD OF USE | PRIMA INNOVATIONS, LLC | 2025-06-12 | — | — | US | claimed |
| EP-4362994-B1 | CROSSLINKED HYALURONIC ACID COMPOSITION WITH LOCAL ANESTHETICS | BIOPOLIMERI S R L (IT) | 2025-03-12 | — | — | EP | claimed |
| EP-3703802-B9 | NASAL DELIVERY DEVICES AND METHODS OF USE THEREOF | CLEXIO BIOSCIENCES LTD (IL) | 2024-12-04 | — | — | EP | claimed |
| EP-3703802-B1 | NASAL DELIVERY DEVICES AND METHODS OF USE THEREOF | CLEXIO BIOSCIENCES LTD (IL) | 2024-10-16 | — | — | EP | claimed |
| US-20240293311-A1 | CROSSLINKED HYALURONIC ACID COMPOSITION WITH LOCAL ANESTHETICS | BIOPOLIMERI S.R.L. (IT) | 2024-09-05 | — | — | US | claimed |
| US-20240261464-A1 | POWDER FORMULATION FOR TISSUE REPAIR, PREPARATION METHOD THEREFOR, AND INJECTABLE COMPOSITION FOR TISSUE REPAIR, COMPRISING SAME | SAMYANG HOLDINGS CORPORATION (KR) | 2024-08-08 | — | — | US | claimed |
| EP-4374885-A1 | POWDER FORMULATION FOR TISSUE REPAIR, PREPARATION METHOD THEREFOR, AND INJECTABLE COMPOSITION FOR TISSUE REPAIR, COMPRISING SAME | Samyang Holdings Corporation (KR) | 2024-05-29 | — | — | EP | claimed |
| US-20030027833-A1 | Compositions and delivery systems for administration of a local anesthetic agent | CORIUM INTERNATIONAL, INC. | 2003-02-06 | — | — | US | claimed |
| WO-2002089849-A1 | COMPOSITIONS AND DELIVERY SYSTEMS FOR ADMINISTRATION OF A LOCAL ANESTHETIC AGENT | CORIUM INTERNATIONAL (US) | 2002-11-14 | — | — | WO | claimed |
| US-6432986-B2 | INTRANOSALLY ADMINISTERING OF ANESTHETICS | BHL PATENT HOLDINGS LLC | 2002-08-13 | — | — | US | claimed |
| US-20010055607-A1 | COMPOSITIONS, KITS, AND METHODS FOR INHIBITING CEREBRAL NEUROVASCULAR DISORDERS AND MUSCULAR HEADACHES | BHL PATENT HOLDINGS LLC | 2001-12-27 | — | — | US | claimed |
| WO-2001080797-A1 | MEDICATED WRAP | HYSON MORTON I (US) | 2001-11-01 | — | — | WO | claimed |
| US-20010004644-A1 | Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation | LEVIN BRUCE H (US) | 2001-06-21 | — | — | US | claimed |
| WO-2001043733-A2 | COMPOSITIONS, KITS, APPARATUS, AND METHODS FOR INHIBITING CEPHALIC INFLAMMATION | LEVIN BRUCE H (US) | 2001-06-21 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010055607-A1 | COMPOSITIONS, KITS, AND METHODS FOR INHIBITING CEREBRAL NEUROVASCULAR DISORDERS AND MUSCULAR HEADACHES | TNNC1, KIT, PDE3A | SCN1A 43/4885SCN2A 137/4885SCN3A 79/4885 |
| US-12329856-B2 | Crosslinked hyaluronic acid composition with local anesthetics | CD44, HCAR3, HCAR2 | SCN1A 2618/4885SCN2A 2486/4885SCN3A 2849/4885 |
| US-20010004644-A1 | Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation | CXCR5, CCL5, C5AR2 | SCN1A 2794/4885SCN2A 3499/4885SCN3A 3081/4885 |
| US-20260115156-A1 | INJECTABLE COMPOSITION INCLUDING HYDROGEL CONTAINING ANESTHETIC AGENT | CES2, DAGLA, ACHE | SCN1A 1562/4885SCN2A 501/4885SCN3A 401/4885 |
| US-20240293311-A1 | CROSSLINKED HYALURONIC ACID COMPOSITION WITH LOCAL ANESTHETICS | CD44, HCAR3, HCAR2 | SCN1A 2618/4885SCN2A 2486/4885SCN3A 2849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.